3 Drugs That Could Make-or-Break AbbVie Post author:Sam Post published:February 11, 2018 Post category:BioPharma A look at three drug approvals of vital importance to the company this year. Source: BioSpace You Might Also Like Life Science Companies are Litigation Targets for Unhappy Investors February 22, 2018 Neos Therapeutics To Host First Quarter 2017 Financial Results Conference Call On May 9, 2017 May 1, 2017 Becton, Dickinson and Company Prices Offerings Of $2.25 Billion Of Common Stock And $2.25 Billion Of Depositary Shares Representing Interests In Mandatory Convertible Preferred Stock May 10, 2017
Neos Therapeutics To Host First Quarter 2017 Financial Results Conference Call On May 9, 2017 May 1, 2017
Becton, Dickinson and Company Prices Offerings Of $2.25 Billion Of Common Stock And $2.25 Billion Of Depositary Shares Representing Interests In Mandatory Convertible Preferred Stock May 10, 2017
